Cargando…

Antifibrotic drugs for idiopathic pulmonary fibrosis: What we should know?

Detalles Bibliográficos
Autores principales:	Hadda, Vijay, Guleria, Randeep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881818/ https://www.ncbi.nlm.nih.gov/pubmed/33107479 http://dx.doi.org/10.4103/ijmr.IJMR_90_20

Ejemplares similares

The Role of Surgical Lung Biopsy in Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
por: Limper, Andrew H.
Publicado: (2019)

ANTIFIBROTIC THERAPY IN IDIOPATHIC PULMONARY FIBROSIS
por: Scullion, T., et al.
Publicado: (2017)

Men's Health: What Should We Know?
por: Kim, Sae Woong
Publicado: (2015)

B Cells in Idiopathic Pulmonary Fibrosis: Targeting Immune Cells with Antifibrotic Agents
por: Roman, Jesse, et al.
Publicado: (2021)

Broad Adoption of Antifibrotics in Idiopathic Pulmonary Fibrosis: Still a Long Way to Go
por: Assayag, Deborah
Publicado: (2021)

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
por: Maher, Toby M., et al.
Publicado: (2019)

Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
por: Sugino, Keishi, et al.
Publicado: (2021)

Benefits of Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Drug Treatment
por: Iwanami, Yuji, et al.
Publicado: (2022)

COVID-19 and Dialysis Units: What Do We Know Now and What Should We Do?
por: Ikizler, T. Alp
Publicado: (2020)

Drug Allergy in Children: What Should We Know?
por: Park, Ji Soo, et al.
Publicado: (2019)

Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis
por: Kang, Jieun, et al.
Publicado: (2021)

Metabolic syndrome: what we know and what we need to know
por: Soares, Raquel
Publicado: (2020)

What We Know and What We Don't Know About Preventing Stroke
por: Burch, Druin
Publicado: (2014)

Goal-directed therapy: what we know and what we need to know
por: O’Neal, Jason B, et al.
Publicado: (2015)

Presbyopia: What We Do Know and What We Do Not Know in 2022
por: Grzybowski, Andrzej, et al.
Publicado: (2023)

Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
por: Kelly, Bryan T., et al.
Publicado: (2021)

Mortality and Respiratory-Related Hospitalizations in Idiopathic Pulmonary Fibrosis Not Treated With Antifibrotics
por: Cottin, Vincent, et al.
Publicado: (2021)

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
por: Collins, Bridget F., et al.
Publicado: (2019)

Antifibrotics and Reduced Mortality in Idiopathic Pulmonary Fibrosis: Immortal Time Bias
por: Suissa, Samy, et al.
Publicado: (2022)

Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry
por: Salisbury, Margaret L., et al.
Publicado: (2020)

Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
por: Proesmans, V. L. J., et al.
Publicado: (2019)

National data on prevalence of idiopathic pulmonary fibrosis and antifibrotic drug use in Finnish specialised care
por: Salonen, Johanna, et al.
Publicado: (2022)

HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis
por: Lyu, Xing, et al.
Publicado: (2019)

Thymic neuroendocrine neoplasms—what we know, what we don’t know, and what to do about it
por: Lang, Matthias, et al.
Publicado: (2023)

Circadian Rhythms in Bacterial Sepsis Pathology: What We Know and What We Should Know
por: Mul Fedele, Malena Lis, et al.
Publicado: (2021)

What We Want to Know
Publicado: (1897)

Multimorbidity: What do we know? What should we do?
por: Navickas, Rokas, et al.
Publicado: (2016)

How Do We Know What We Are Missing? Loss of Signaling through CD148 Drives Fibroblast Activation in Pulmonary Fibrosis
por: Redente, Elizabeth F.
Publicado: (2021)

Antifibrotic therapy in idiopathic pulmonary fibrosis candidates for lung transplantation undergoing pulmonary rehabilitation
por: Pereira, Monica Pruss, et al.
Publicado: (2023)

Abdominal distension following radical cystectomy: what we know and what we need to know
por: Hanna, Peter
Publicado: (2022)

COVID-19 in Children: What We Know and What We Don’t Know?
por: Jat, Kana Ram
Publicado: (2021)

What Surgeon Should Know about Probiotics
por: Kotzampassi, Katerina
Publicado: (2022)

Cryoprobe transbronchial lung biopsy: How we do it?
por: Madan, Karan, et al.
Publicado: (2018)

Effect of genotype on the disease course in idiopathic pulmonary fibrosis despite antifibrotic treatment
por: Sterclova, Martina, et al.
Publicado: (2021)

Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication
por: Seeliger, Benjamin, et al.
Publicado: (2022)

Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series
por: Delanote, Isabelle, et al.
Publicado: (2016)

Pregnancy and antibody-mediated CNS disorders: What do we know and what should we know?
por: Cortese, Rosa, et al.
Publicado: (2022)

The filling defect of pulmonary artery, an imaging finding what we should know
por: Liu, Min, et al.
Publicado: (2020)

COVID-19—What we know and what we need to know: There are more questions than answers
por: Maisch, Bernhard, et al.
Publicado: (2020)

Autoimmune Hepatitis in Iran: What We Know, What We Don’t Know and Requirements for Better Management
por: Shafiei, Mostafa, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6o6tuojran2bb74f4mb2n4in1k